Identification of predictive parameters for typhlitis in AML patients treated with intensive chemotherapy

Completed

• Conditions: AML; leukemia; 10024324

• Registration Number: NL-OMON31938
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 45

Inclusion Criteria

- age 18-70 years
- patients with AML treated with intensive chemotherapy

Exclusion Criteria

Ineligible to perform the proposed tests.

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- Defining the severity of epithelial dysfunction measured with mucositis<br /><br>score; the stool volume; the calprotectin level in the stool the urinary Cr<br /><br>EDTA excretion and serum IL-8 and CRP levels.<br /><br>- Typhlitis based on clinical symptomatology and CT-scanning abdomen.<br /><br>- DNA isolation from normal peripheral blood cells for determining polymorphism<br /><br>of metabolism genes.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable.</p><br>